Showing results (101-110 of 252) with videos related to

Sort By:
Pageof 26
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2023
Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid LeukemiaAkriti G Jain, Somedeb Ball, Luis E Aguirre, et al.
Journal of Cardiovascular Pharmacology|April 25, 2018
Tranilast Blunts the Hypertrophic and Fibrotic Response to Increased Afterload Independent of Cardiomyocyte Transient Receptor Potential Vanilloid 2 ChannelsSheryl E Koch, Michelle L Nieman, Nathan Robbins, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2020
Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase KaryotypeZaker I Schwabkey, Najla Al Ali, Onyee Chan, et al.
Cancer|August 9, 2022
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlatesAndrew T Kuykendall, Qianxing Mo, David A Sallman, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|March 3, 2006
Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8Michael Douglas Lane, Hyun Joo Nam, Eric Padron, et al.
Plos One|December 4, 2014
Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitorsKathy L McGraw, Ashley A Basiorka, Joseph O Johnson, et al.
Leukemia Research|January 21, 2014
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failureMichael V Jaglal, Vu H Duong, Celeste M Bello, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 15, 2018
Tefillin use induces remote ischemic preconditioning pathways in healthy menA Phillip Owens, Nathan Robbins, Keith Saum, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2017
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib ApprovalAndrew T Kuykendall, Chetasi Talati, Najla Al Ali, et al.
Blood|November 7, 2024
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigmAnthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, et al.
Pageof 26